Evidence map›Paper›PMID 35241697›Full record

ArticleNPJ Parkinson's disease2022

Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers.

Amgad Droby, Moran Artzi, Hedva Lerman, R Matthew Hutchison, Dafna Ben Bashat, Nurit Omer, Tanya Gurevich, Avi Orr-Urtreger, Batsheva Cohen, Jesse M Cedarbaum and 4 more

Open access · goldAbstract read
In one paragraph

Article in NPJ Parkinson's disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Neuromelanin and TNPJ Parkinson's disease · 2022
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Amgad DrobyMovement Disorders Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel. amgadd@tlvmc.gov.il.ORCID http://orcid.org/0000-0002-6182-0059
Moran ArtziSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Hedva LermanSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
R Matthew HutchisonBiogen Inc, Cambridge, MA, USA.
Dafna Ben BashatSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Nurit OmerMovement Disorders Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel.
Tanya GurevichMovement Disorders Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel.
Avi Orr-UrtregerMovement Disorders Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel.
Batsheva CohenMovement Disorders Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel.
Jesse M CedarbaumCoeruleus Clinical Sciences LLC, Woodbridge, CT, USA.
Einat Even SapirSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Nir GiladiMovement Disorders Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel.
Anat MirelmanMovement Disorders Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel.
Avner ThalerMovement Disorders Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel.
Tel Aviv University · ILBiogen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-manifesting carriers (NMCs) of Parkinson's disease (PD)-related mutations such as LRRK2 and GBA are at an increased risk for developing PD. Dopamine transporter (DaT)-spectral positron emission computed tomography is widely used for capturing functional nigrostriatal dopaminergic activity. However, it does not reflect other ongoing neuronal processes; especially in the prodromal stages of the disease. Resting-state fMRI (rs-fMRI) has been proposed as a mode for assessing functional alterations associated with PD, but its relation to dopaminergic deficiency remains unclear. We aimed to study the association between presynaptic striatal dopamine uptake and functional connectivity (FC) patterns among healthy first-degree relatives of PD patients with mutations in LRRK2 and GBA genes. N = 85 healthy first-degree subjects were enrolled and genotyped. All participants underwent DaT and rs-fMRI scans, as well as a comprehensive clinical assessment battery. Between-group differences in FC within striatal regions were investigated and compared with striatal binding ratios (SBR). N = 26 GBA-NMCs, N = 25 LRRK2-NMCs, and N = 34 age-matched nonmanifesting noncarriers (NM-NCs) were included in each study group based on genetic status. While genetically-defined groups were similar across clinical measures, LRRK2-NMCs demonstrated lower SBR in the right putamen compared with NM-NCs, and higher right putamen FC compared to GBA-NMCs. In this group, higher striatal FC was associated with increased risk for PD. The observed differential SBR and FC patterns among LRRK2-NMCs and GBA-NMCs indicate that DaTscan and FC assessments might offer a more sensitive prediction of the risk for PD in the pre-clinical stages of the disease.

Identifiers

PMID35241697
PMCPMC8894349
OpenAlexW4220778395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.